alexa
Reach Us +1 218 451 2974
Kisspeptin ? A Possible Drug-candidate For Mental And Cognitive Disorders | 2515
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Kisspeptin ? a possible drug-candidate for mental and cognitive disorders

International Conference on Central Nervous System - Drug Effects & Novel Drug Development

Michal Cardon, Matityahu Fridkin and Michal Schwartz

ScientificTracks Abstracts: J Neurol Neurophysiol

DOI: 10.4172/2155-9562.S1.003

Abstract
Kisspeptins are a family of proteins that are known as regulators of sex hormones. Recently, we found that abnormal sensorimotor gating (measured in paradigms of prepulse inhibition; PPI) in immune deficient mice (SCID) and the poly I:C model for developmental schizophrenia is correlated to irregular expression of Kisspeptin. Systemic IP injection of the Kisspeptin-derived peptide, Kp-10, enhanced PPI in a dose-dependent manner, while a Kisspeptin receptor antagonist reduced PPI. Furthermore, Kisspeptin can improve performance in several models of behavioral disorders including reduced PPI induced by poly I:C or MK-801, disturbed learning and memory in SCID mice or induced by MK-801, and behavioral despair. The effect of Kisspeptin on PPI was found to be mediated via neurotensin, a neuropeptide known to be related to several CNS disorders. Kp-10, the peptide used in our studies, is a 10 amino acid peptide and may not be stable enough to use in mental and cognitive disorders in humans. Therefore, we produced several Kp-10 derivatives with improved pharmaceutical properties; two of these analogs exhibit antipsychotic activity in vivo in the MK-801 mouse model for schizophrenia. The performance of one of these peptides, a 6 amino acid cyclic peptide, was better in this model than that of the original Kp-10. Our results indicate that this cyclic peptide might be a suitable drug candidate for disorders involving PPI, learning and memory or behavioral despair such as schizophrenia, depression, Alzheimer?s disease and other age-related dementias.
Biography
Michal Cardon completed her PhD, and started her postdoctoral studies in 2010 at the Weizmann Institute of Science. She has published more than 9 papers in reputed journals
Relevant Topics
Top